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ABSTRACT
Introduction: In 2017, the International League Against Epilepsy (ILAE)
published a new classification of seizures. The purpose of this publication is to
analyze the use of antiepileptic drugs in epilepsy therapy depending on the types
of seizures classified according to ILAE 2017.
329
State of the art: The new basic classification emphasizes mainly the location,
where seizures begin in the brain, as the most important criterion to classify
epileptic seizures. In focal onset seizures, 1st line of treatment in children is
oxcarbazepine, while carbamazepine, levetiracetam, phenytoin and zonisamide is
1st choice in younger adults and gabapentin and lamotrigine in elderly patients.
In younger adults valproic acid can be considered as second line treatment. In
generalized tonic and atonic seizures carbamazepine, phenobarbital, phenytoin,
topiramate, oxcarbazepine and valproic acid can be used both in children and
adults. Safe and effective drugs in myoclonic and myoclonic-atonic seizures in all
age groups are topiramate and valproic acid. In absence seizures, 1st line
treatment in children is ethosuximide (used exclusively in this seizures type) and
valproic acid, while carbamazepine, lamotrigine, oxcarbazepine, phenobarbital,
phenytoin, topiramate, valproic acid, gabapentin, levetiracetam and vigabatrin
are commonly used in adult patients. Non-pharmacological approaches, used in
refractory epilepsy, include: surgical resection of the seizure focus, the ketogenic
diet, vagus nerve stimulation and responsive neurostimulation.
Summary: The new ILAE classification corresponds well with the old guidelines
well, which leads to simplifying and spreading the knowledge about epileptic
seizures treatment.
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1. INTRODUCTION
In 2017, the International League Against Epilepsy (ILAE) published a
new classification of seizures. Although the old classification is still used in
clinical practice, especially by non-neurologists, it is important to
understand how changing perceptions of different types of epileptic
seizures and the change of terminology affect the timeliness of
recommendations for antiepileptic drug therapy. The purpose of this
publication is to analyze the use of antiepileptic drugs in epilepsy therapy
depending on the types of seizures classified according to ILAE 2017.
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Figure 1. ILAE 2014 revised definition of epilepsy. [2]
1.1. New ILAE Classification
The new basic classification emphasizes 3 key features:
the location, where seizures begin in the brain
the level of awareness of the patient during an epileptic seizure
other features of seizures are also taken into account. [1]
The new names of epileptic seizures, together with the corresponding
terms from the old classification, are presented in Table 1.
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Table 1. Names of seizures from old classification and the corresponding
terms which replaced them.
Old classification New classification
Simple partial Focal aware
Complex partial Focal impaired awareness
Primary generalized Generalized
Secondary generalized Focal to bilateral
Figure 1. ILAE 2017 Classification of Seizure Types Basic Version [1]
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2. RESULTS
The treatment recommendations for different types of seizures were
retrieved from various publications, some of which were published before
2017 ILAE guidelines update – in these cases the change of nomenclature
was taken into account.
2.1. Focal onset seizures treatment
For the treatment of focal onset seizures in children, the 1st choice
medication stays oxcarbazepine. However, depending on clinical
conditions, the drugs which are also possible to use are: carbamazepine,
phenobarbital, phenytoin, topiramate, valproic acid, vigabatrin, clobazam,
clonazepam, lamotrigine, zonisamide.
In adults aged 16-59 years old, the 1st choice treatment are
carbamazepine, levetiracetam, phenytoin and zonisamide. The second line
drug is valproic acid, while gabapentin, lamotrigine, oxcarbazepine,
phenobarbital, topiramate, vigabatrin, clonazepam and primidone are also
possible.
In elderly patients gabapentin or lamotrigine should be used first.
Carbamazepine, topiramate or valproic acid can be considered either. [1-6]
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Figure 2. First and second treatment choices in focal onset seizures.
Table 2. Other possible treatment approaches in focal onset seizures
depending on the age group
Age group Other treatment possibilities
Children carbamazepine, phenobarbital, phenytoin,topiramate, valproic acid, vigabatrin, clobazam,clonazepam, lamotrigine, zonisamideAdults 16-59years old gabapentin, lamotrigine, oxcarbazepine,phenobarbital, topiramate, vigabatrin,clonazepam, primidoneAdults ≥ 60years old carbamazepine, topiramate, valproic acid
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2.2. Generalized onset seizures treatment
2.2.1. Tonic and atonic seizures treatment
In these kind of generalized onset seizures, the medications that can
be used are carbamazepine, phenobarbital, phenytoin, topiramate,
oxcarbazepine and valproic acid. Additionally, lamotrigine, gabapentin,
levetiracetam and vigabatrin can be also used in adult patients. [1-6]
Figure 3. Treatment approaches in tonic and atonic generalized onset
seizures.
2.2.2. Myoclonic and myoclonic-atonic seizures treatment
Topiramate and valproic acid can be used either in children and in
adults to treat myoclonic or myoclonic-atonic seizures. Moreover,
carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, phenytoin,
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gabapentin, levetiracetam and vigabatrin are admissible in adults either.
[1-6]
Figure 4. Treatment approaches in myoclonic and myoclonic-atonic
generalized onset seizures.
2.2.3. Absence seizures treatment
Ethosuximide and valproic acid are 1st choice treatment for absence
generalized onset seizures in children, while lamotrigine is also possible. In
adults, numerous medications including carbamazepine, lamotrigine,
oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid,
gabapentin, levetiracetam and vigabatrin are used in this type of epileptic
seizures. [1-6]
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Figure 5. Treatment approaches in generalized onset absence seizures in
children.
Figure 6. Treatment options in absence generalized onset seizures inadults.
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2.2.4. Important limitations
Practically the only antiepileptic drug, that can be successfully used
in all kinds of epileptic seizures (both generalized and focal onset) is
valproic acid, although it is the 1st line treatment in only some of them.
Carbamazepine, oxcarbazepine, gabapentine, pregabaline,
phenytoine and vigabatrin can provoke even more absence and myoclonic
attacks (generalized onset seizures), thus they should not be used in
individuals presenting these kind of seizures.
Moreover, although carbamazepine and oxcarbazepine are
sometimes used in tonic and atonic generalized onset seizures, they are
proven to increasing risk of provoking generalized myoclonic and absence
seizures therefore caution should be exercised when using these drugs.
Ethosuximide is used specifically for absence seizures treatment in
children. [1-6]
2.3. Non-pharmacological approaches
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Figure 7. Non-pharmacological approaches in refractory epilepsy.
Possible non-pharmacological approaches in epilepsy treatment,
used when medications do not effect in seizures remission, is depicted in
Figure 7.
3. CONCLUSIONS
An increasing number of antiepileptic drugs contributes to wider
therapeutic options. It is important to match the medication to the
patient's seizure accordingly to the new ILAE classification, where the
place of initiation of an epileptic seizure in the brain should be considered
first. Only then positive treatment effects can be expected, because not all
antiepileptic drugs are effective in all types of seizures (although there are
those that can be successfully used in almost any type of seizure, e.g.
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valproic acid), and in some cases they may even be contraindicated
because they may increase the risk of other types seizures. It should be
noted that some of the medications that can be successfully used in adults
have not been approved for use in children in the guidelines, or are at
least are not the first choice therapeutic option. Even despite properly
selected treatment, some patients fail to achieve longer periods free of
seizures. In case of refractory epilepsy it is vital to remember about non-
pharmacological approach, including surgical resection of the seizure
focus, the ketogenic diet, vagus nerve stimulation or responsive
neurostimulation.
Figure 8. Circumstances that should be taken into account while choosing
antiepileptic drugs.
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Table 3. Potential teratogenicity of antiepileptic drugs in pregnancy. [6]
HIGHTERATOGENICITY Valproicacid
Carbamazepine
Topiramate
Phenytoin
Phenobarbital
Clonazepam
Gabapentin
Lamotrigine
Levetiracetam
LOWTERATOGENICITY
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